The activated human Ha
Wap-ras-i.e., mammary or salivary glands. Compared to the corresponding nonmalignant tissues, Wap-ras expression was enhanced in the tumors.
The identification of oncogenes and the molecular mechanisms by which protooncogenes can be activated has provided a basis for the description of cancer as a genetic disease. A relatively small number of genes is able to subvert the growth program of cells and cause malignant transformation (1) . In vivo and in vitro transformation studies indicate that tumorigenesis is a multistep process. The establishment of cell lines and their malignant transformation are two processes that can be distinguished in in vitro studies. The activated form of the Ha-ras oncogene has been shown to confer a stable tumorigenic phenotype to most established cell lines. Low levels of Ha-ras protein are not sufficient to transform primary rat fibroblasts. A second oncogene, which provides an establishment function (e.g., myc-, the pS3-, or the Ela gene), is required (2) (3) (4) . Additional genes and mutations may be crucial for tumorigenesis in vivo (5, 6) .
The recent progress in obtaining transgenic mice that faithfully express foreign genes encourages the adaptation of this system for studies of oncogene effects in vivo. The information responsible for cell-type-specific gene expression is often located in the surroundings ofthe gene promoter. Recombination of these regulatory sequences has generally been sufficient to target chimeric gene expression in transgenic mice (7) . This raises the possibility of analyzing the effect of an experimentally introduced oncogene on a particular cell type in vivo by coupling the oncogene to a tissue-specific promoter. The rat insulin II gene promoter directs the expression of the large tumor antigen (large T antigen) of simian virus 40 to the P cells of the endocrine pancreas in transgenic mice (8) . The metallothionein gene promoter allows large T-antigen expression in liver cells (9) . In both cases, tumors were observed in the T-antigenexpressing cells. The mouse mammary tumor virus-controlled expression of the myc oncogene in the mammary gland subsequently leads to mammary tumor formation (10) . myc expression directed by the heavy-and light-chain immunoglobulin enhancers leads to the transformation of B lymphocytes in transgenic mice (11) .
Our interest in transformation of mammary epithelial cells led us to study the effect of a specific oncogene on this particular cell type in vivo. Therefore, we introduced the activated human Ha-rasT oncogene under the putative control region of the murine whey acidic protein (Wap) gene into the genome of mice. The Wap is the major whey protein in the milk of rodents (13) . The expression of the gene is regulated by the lactogenic hormone prolactin and is modulated by insulin and hydrocortisone. With the onset of lactation, Wap is synthesized in the differentiated mammary epithelial cells (14, 15 (12) .
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The details of the Wap-ras construct are given in Fig. 1 .
For cloning procedures, standard protocols were followed (17) . The Wap-ras gene was purified from vector sequences and was injected as linear 7.4-kb EcoRI/HindIII fragment into fertilized eggs (-200 copies per egg) of C57BL6 x SJL hybrid crosses. Microinjections were done as described (18) and the eggs were reimplanted on the same day into pseudopregnant recipients.
DNA Analysis. DNA was prepared frpm tails of 3-to 4-week-old mice. Wap-ras sequences were routinely detected by the dot blot hybridization technique using 5 ug of tail DNA (18) . For restriction digestions, the DNA was further treated with RNase and proteinase K. Digested DNAs were separated on 0.8% agarose gels and analyzed according to Southern (19) . RNA Analysis. Cytoplasmic RNA from various tissues was prepared essentially as described by Brawermann et al. (20) . After separation from the nuclei, the cytoplasmic supernatant was extracted twice with phenol using an extraction buffer containing 0.15 M Tris HCl, 5 mM EDTA, and 1% sodium dodecyl sulfate (pH 9.0). The RNA was analyzed by RNase protection assays as described (21 (7) . To study the possible involvement of Ha-ras expression in the transformation process of mammary epithelial cells, the coding part of the activated human Ha-ras gene was subjected to the control region of the mammary gland-specific murine Wap gene. The Wap gene is expressed in mammary epithelial cells during lactation (14) . We linked the putative control region of the murine Wap gene contained within a 2.5-kb EcoRI/Kpn I fragment encoding the sequences up to one nucleotide 5' of the translation start codon AUG to the Ha-ras oncogene. The restriction maps of the two genes and the resulting Wap-ras construct are shown in Fig. 1 . The Wap-ras hybrid gene was purified from most vector sequences by EcoRI and HindIII digestion before injection. Then 560 fertilized eggs were injected and 71 mice were born. A dot blot analysis of tail DNA was carried out and five animals (female nos. 3, 11, 40, and 58; male no. 69) were found to contain the injected sequences.
DNA blot analysis was used to investigate the presence, the integrity, and the approximate copy number of the Wap-ras gene in transgenic mice. DNA was digested with EcoRI and HindIII and blots were hybridized to a Ha-rasspecific probe ( Fig. 2A) . During the integration event, it is likely that the flanking EcoRI and HindIII restriction sites of the injected DNA are lost (22 gland-specific and lactogenic hormone-regulated Wap-ras expression, we analyzed the RNA of different tissues of transgenic animals for Wap-ras and for endogenous Wap sequences by RNase protection assays. To detect the Wap-ras RNA, we used a probe (Xba I/Pst I; Fig. 3) indicative for exon 1 of the hybrid gene that protects a fragment of 143 nucleotides. Endogenous Wap RNA can be detected by a probe that protects two fragments indicative for exon 1 (110 nucleotides) and exon 2 (135 nucleotides) of the murine Wap gene. Fig. 3 shows the Wap-ras expression pattern in organs of a female representing line 3. The fourth mammary gland was surgically removed during the lactation period and the RNA was analyzed. Two weeks after the end of lactation, the animal was sacrificed and RNA was prepared from mammary glands, spleen, liver, lung, kidney, ovary, and brain. Wap-ras =50-fold difference in the Wap and Wap-ras mRNA concentrations.
We investigated whether the hormonally controlled expression of the Wap-ras gene is confined to the mammary gland. RNA from different tissues of a lactating female of line 3 was isolated and analyzed for Wap-ras expression. The results of RNase protection assays are shown in Fig. 4A . Wap-ras RNA was detected in the mammary gland (lane 1) and in brain tissue of lactating females (lane 3). The brain is known to express a high proportion of the genetic information (23) and might exert less restrictions on transcription than other tissues. It is interesting to note that the expression of the Wap-ras gene is still hormonally regulated in the brain (Fig. 3, lane 8; Fig. 4, lane 3) . No Wap-ras RNA was detected in the muscle (lane 2), kidney, liver, spleen, lung, and ovaries (lanes 4-8) of a lactating female. The endogenous Wap RNA was only found in the lactating mammary gland. In other organs, we found no Wap expression. In the males of these lines, neither Wap-ras nor Wap RNA was detected in salivary gland, testis, brain, kidney, liver, lung, spleen, and muscle. Wap-ras expression was only found in mammary gland and brain of lactating animals of lines 3 and 58. We conclude that in these two transgenic lines the Wap fragment restricts ras expression to these two tissues and confers hormonal regulation. In females and males of lines 11 and 40, we failed to detect Wap-ras expression.
We analyzed the Wap-ras expression in males of line 69. In this line, the chimeric gene is integrated into the Y chromosome. The 143-nucleotide fragment indicative of the Wap-ras RNA was detected in the salivary gland RNA by RNase protection assays (Fig. 4B) . All other male organs tested (liver, kidney, testes, brain, spleen, muscle, and lung) do not show Wap-ras expression. Expression of the transgene in salivary glands was not found in males of the other transgenic lines. It is peculiar to line 69 and may be based on the integration of the transgene into the Y chromosome.
The probe we used to detect Wap-ras RNA does not contain the transcriptional initiation site. RNase protection assays were done on RNA prepared from lactating mammary glands, salivary glands, and tumor tissue (see below) using a probe indicative only for the Wap and the linker sequences of the hybrid gene (i.e., a 0.4-kb Sac I/BamHI fragment; see to the linker sequences of the probe (data not shown). Using the same probe, we found a 19-nucleotide protected fragment after hybridization to endogenous Wap RNA. This is consistent with the previously mapped RNA initiation site (15) . The Wap-ras RNA starts within the linker sequence between the Wap and the ras fragment. We assume that the construction of the hybrid gene created new sequences that can be used as the RNA start site in the transgenic animals.
Wap-ras Expression in Tumors of Transgenic Animals. The tissue-specific expression of the ras oncogene in mammary glands of lines 3 and 58 and salivary glands of line 69 allowed us to investigate the phenotypic consequences of the presence of an activated oncogene product in these animals. Initially, the animals were morphologically normal and healthy. Only after a long latency did some of the animals develop tumors. We found two mammary tumors in the founder female no. 58 at the age of 325 days after having given birth to her fifth litter. Three weeks after parturition, RNA was prepared from both tumors and from the fourth histologically normal mammary gland and analyzed for the presence of Wap-ras sequences (Fig. 5A ). Wap-ras RNA was detected in both tumors (lanes 2 and 3) . The level of Wap-ras RNA is strongly enhanced in the malignant tissues compared to the normal mammary gland (lane 1). The endogeneous Wap RNA remains low in the tumor (lane 5) and in the normal mammary gland (lane 4). This low level of Wap RNA is consistent with the hormonal state of the animal near the end of the lactating period.
In line 69, the Wap-ras gene is constitutively expressed in the salivary gland. Five animals developed tumors in the neck region at the age of 9 months. The histological examination classified these as adenocarcinomas derived from the salivary gland. The Wap-ras RNA is present at high levels in all tumors compared to the levels found in the nonmalignant corresponding salivary gland of the same individual. The RNA analysis of two of these tumors and normal salivary tissue is shown in Fig. SB (lanes 1-3) . Hybridization experiments with an a-amylase-specific probe (24) (30) . However, analysis of dose-response curves suggests that at least two events are required for transformation (31) . A similar situation was described for transgenic mice bearing the c-myc oncogene fused to the long terminal repeat of the mouse mammary tumor virus (10, 32) . The possibility of secondary mutations might increase with age. This could result in expression of cooperating oncogenes.
In 
